Argenx B.V.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Argenx Bvba (to 2022)
7
Ending by 2030
Jul 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for FCRN Antagonists and Methods of Use (US 10,316,073) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 1 fee due Jan 25, 2027The maintenance fee for Antibodies to Human Complement Factor C2B and Methods of Use (US 11,708,403) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 2 fees due Feb 1, 2027
- 1 fee due May 26, 2027The maintenance fee for Asymmetric Multispecific Antibodies (US 10,487,156) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 1 fee due Jun 29, 2027The maintenance fee for Antigen Binding Polypeptides (US 9,221,918) comes due Jun 29, 2027. Unpaid by Dec 29, 2027, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Antibody Against a Complex Between Human Garp and Latent TGF Beta (US 10,604,579) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Antigen Binding Polypeptides (US 9,315,576) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,221,918 | Antigen Binding Polypeptides In force · High confidence | In force | High confidence | |
| US 9,315,576 | Antigen Binding Polypeptides In force · High confidence | In force | High confidence | |
| US 9,346,891 | Antigen Binding Polypeptides In force · High confidence | In force | High confidence | |
| US 9,540,437 | Humanized Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 8,524,231 | Antigen Binding Polypeptides In force · Medium confidence | In force | Medium confidence | |
| US 8,835,607 | Humanized Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 8,444,976 | Antigen Binding Polypeptides In force · High confidence | In force | High confidence | |
| US 8,637,027 | Anti C-Met Antibodies In force · High confidence | In force | High confidence | |
| US 9,631,027 | Anti C-Met Antibodies In force · High confidence | In force | High confidence | |
| US 9,688,774 | Anti C-Met Antibodies In force · High confidence | In force | High confidence |
Also on record, not counted in the 54: 2 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
25 pending · 15 abandoned · 3 no status recorded